RecruitingNot applicableNCT06765590

Bioequivalence Study of Paclitaxel for Injection (Albumin Bound) in Subjects With Breast Cancer

Studying Chronic bilirubin encephalopathy

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Sichuan Huiyu Pharmaceutical Co., Ltd
Intervention
T, 260 mg/m2, paclitaxel for injection (albumin-bound)(drug)
Enrollment
24 target
Eligibility
18-75 years · All sexes
Timeline
20252026

Study locations (1)

Collaborators

The First Hospital of Jilin University · The First Affiliated Hospital of Bengbu Medical University · Chongqing Traditional Chinese Medicine Hospital · The First Affiliated Hospital of Henan University of Science and Technology · Qianfoshan Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06765590 on ClinicalTrials.gov

Other trials for Chronic bilirubin encephalopathy

Additional recruiting or active studies for the same condition.

See all trials for Chronic bilirubin encephalopathy

← Back to all trials